secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001808805-26-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend
--------------------------------------------------------------------------------

- Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.
- FY2025 net loss of $59.0M vs $70.8M in FY2024; operating expenses fell 18% to $66.8M.
- Cash and investments $156.1M as of Dec 31, 2025; management sees sufficient runway through 2027.
- Early Access Program launched Jan 2026 for Tau proteoforms; no material revenue expected in FY2026.
- FY2026 operating expenses expected to increase 15-20% YoY; full commercial launch targeted late 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880526000004/0001808805-26-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880526000004/naut-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001808805-26-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer